Where and Why Modeling Amyotrophic Lateral Sclerosis

Int J Mol Sci. 2021 Apr 12;22(8):3977. doi: 10.3390/ijms22083977.

Abstract

Over the years, researchers have leveraged a host of different in vivo models in order to dissect amyotrophic lateral sclerosis (ALS), a neurodegenerative/neuroinflammatory disease that is heterogeneous in its clinical presentation and is multigenic, multifactorial and non-cell autonomous. These models include both vertebrates and invertebrates such as yeast, worms, flies, zebrafish, mice, rats, guinea pigs, dogs and, more recently, non-human primates. Despite their obvious differences and peculiarities, only the concurrent and comparative analysis of these various systems will allow the untangling of the causes and mechanisms of ALS for finally obtaining new efficacious therapeutics. However, harnessing these powerful organisms poses numerous challenges. In this context, we present here an updated and comprehensive review of how eukaryotic unicellular and multicellular organisms that reproduce a few of the main clinical features of the disease have helped in ALS research to dissect the pathological pathways of the disease insurgence and progression. We describe common features as well as discrepancies among these models, highlighting new insights and emerging roles for experimental organisms in ALS.

Keywords: Caenorhabditis elegans; Danio rerio; Drosophila melanogaster; Saccharomyces cerevisiae; amyotrophic lateral sclerosis; animal modeling; canines; non-human primates; rodents.

Publication types

  • Review

MeSH terms

  • Amyotrophic Lateral Sclerosis / genetics*
  • Amyotrophic Lateral Sclerosis / pathology
  • Amyotrophic Lateral Sclerosis / therapy
  • Animals
  • Animals, Genetically Modified / genetics*
  • Caenorhabditis elegans / genetics
  • Disease Models, Animal
  • Dogs
  • Guinea Pigs
  • Humans
  • Mice
  • Neurodegenerative Diseases / genetics*
  • Neurodegenerative Diseases / pathology
  • Neurodegenerative Diseases / therapy
  • Rats
  • Zebrafish / genetics